- Home
- BROG vs LXRX Comparison
BROG vs LXRX Comparison
Compare BROG & LXRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BROG
- LXRX
- Stock Information
- Founded
- BROG 2019
- LXRX 1995
- Country
- BROG United Arab Emirates
- LXRX United States
- Employees
- BROG N/A
- LXRX N/A
- Industry
- BROG Integrated oil Companies
- LXRX Biotechnology: Pharmaceutical Preparations
- Sector
- BROG Energy
- LXRX Health Care
- Exchange
- BROG Nasdaq
- LXRX Nasdaq
- Market Cap
- BROG 131.5M
- LXRX 124.4M
- IPO Year
- BROG N/A
- LXRX 2000
- Fundamental
- Price
- BROG $1.32
- LXRX $0.70
- Analyst Decision
- BROG
- LXRX Buy
- Analyst Count
- BROG 0
- LXRX 4
- Target Price
- BROG N/A
- LXRX $3.67
- AVG Volume (30 Days)
- BROG 5.5K
- LXRX 5.7M
- Earning Date
- BROG 05-20-2025
- LXRX 05-13-2025
- Dividend Yield
- BROG N/A
- LXRX N/A
- EPS Growth
- BROG N/A
- LXRX N/A
- EPS
- BROG 0.05
- LXRX N/A
- Revenue
- BROG $76,472,340.00
- LXRX $31,081,000.00
- Revenue This Year
- BROG N/A
- LXRX N/A
- Revenue Next Year
- BROG N/A
- LXRX $84.78
- P/E Ratio
- BROG $25.83
- LXRX N/A
- Revenue Growth
- BROG N/A
- LXRX 2481.48
- 52 Week Low
- BROG $0.80
- LXRX $0.28
- 52 Week High
- BROG $2.14
- LXRX $2.45
- Technical
- Relative Strength Index (RSI)
- BROG 59.96
- LXRX 60.07
- Support Level
- BROG $1.15
- LXRX $0.63
- Resistance Level
- BROG $1.28
- LXRX $0.71
- Average True Range (ATR)
- BROG 0.06
- LXRX 0.07
- MACD
- BROG 0.01
- LXRX -0.00
- Stochastic Oscillator
- BROG 100.00
- LXRX 55.00
About BROG Brooge Energy Limited
Brooge Energy Ltd is an Oil Refinery & Storage Company in the United Arab Emirates. The company generates revenue from the leasing of storage capacity of tanks and other ancillary services.
About LXRX Lexicon Pharmaceuticals Inc.
Lexicon Pharmaceuticals Inc is a biopharmaceutical company. It is engaged in the discovery, development, and commercialization of pharmaceutical products for the treatment of human diseases. Some of its drug candidates are LX9211, an orally-delivered small molecule drug candidate, as a treatment for neuropathic pain; and sotagliflozin, an orally-delivered small molecule drug candidate, as a treatment for heart failure and type 1 diabetes.